Clinical evidence dossier
Continuous glucose monitoring
Time above range
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 4
- Supporting studies available for review
- 4
- Randomized trials
- 2
- Reported effects
- 10
Clinical conclusion
Continuous glucose monitoring has a small positive evidence signal for Time above range, but the clinical interpretation is limited.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
−6% to 6%
Change from baseline
Absolute change
5.8 percentage points to 5.8 percentage points
Between-group effect
Mean difference
−6.55% to 7.46%
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 2
- Magnitude-eligible effects
- 6
Consistency
Consistency classification
Mixed
- Positive
- 2
- No effect
- 1
- Mixed
- 0
- Negative
- 1
Population and applicability
Structured population data were available for 4 of 4 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults aged 18-65 with type 2 diabetes
- Individuals classified as obese with a BMI over 30 kg/m²
- Patients with chronic pancreatitis.
- Individuals with insulin-treated diabetes.
- Adults with diabetes seeking improved management strategies
- Patients utilizing community pharmacy services for diabetes care
- Individuals with Type 1 diabetes managing their condition.
- Individuals with Type 2 diabetes seeking improved glycemic control.
Limitations
- Upstream consistency scoring indicates mixed findings across the evidence.
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.
- 2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.
- 3 of 4 studies with duration data have follow-up of 12 weeks or less.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.